CAMBRIDGE, Mass., Oct. 1 MA-Gene-Net-Sciences
CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS)
today announced that it has entered into an agreement with Biogen Idec under
which GNS will use its proprietary REFS(TM) software platform to process
clinical data provided by Biogen Idec to identify targets and biomarkers in
inflammation. A forward simulation model generated directly from the Biogen
Idec data will be licensed to Biogen Idec at the conclusion of this project.
Financial terms of the agreement were not disclosed.
GNS employs massively parallel supercomputers to probe vast amounts of raw
human biological data to discover new insights into the biological causes of
human disease, and new opportunities for diagnosis and treatment. Under this
agreement, GNS will use its REFS(TM) (Reverse Engineering/Forward Simulation)
platform to transform genetic, genomic, and clinical data provided by Biogen
Idec to generate and score billions of hypotheses to discover new drug targets
and biomarkers rapidly.
"Our proprietary technology is capable of taking raw 'omic' data and
running billions of calculations in a short period of time to find potential
biomarkers and promising drug targets that could lead to more effective
patient treatments," said Colin Hill, CEO of GNS. "It is the value and speed
of our REFS(TM) technology and the potential it offers to the Biogen Idec drug
development program that forged our partnership."
About REFS(TM)
Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that
systematically turns multiple layers of biologically relevant data into an
unprecedented view of human biology and disease as a "whole." REFS(TM) begins
with raw biological data (genetic, genomic, epigenetic, proteomic, metabolomic
and environmental) and rapidly performs billions upon billions of calculations
to determine how the molecules interact with one another in the complete
system (Reverse Engineering). These computer-assembled models are then queried
rapidly through billions of in silico experiments (Forward Simulation) to
discover the highest-impact molecular targets for the disease being studied
and the corresponding efficacy and toxicity markers related to specific drug
treatments. These findings are then tested in both the laboratory and the
clinic, enabling a faster, more focused and more effective drug discovery and
development process.
About Gene Network Sciences
Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com/) is a
leader in biosimulation with its ability to derive molecular mechanisms of
drugs and diseases directly from molecular profiling and clinical data without
any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses
its REFS(TM) (reverse engineering and forward simulation) technology in
pharmaceutical and clinical settings to rapidly turn complex and heterogeneous
data sets into cell and organ-level computer models of disease biology, drug
efficacy and drug safety. These models simulate mechanisms of disease and the
clinical performance of drug candidates. By discovering how and why specific
drug candidates impact human biology, GNS technology enables the rapid
development of breakthrough drug and diagnostic products.
For more Information, please contact:
Lynn Blenkhorn Thomas Neyarapally
Feinstein Kean Healthcare Gene Network Sciences, Inc.
508-851-0930617-494-0492
Lynn.blenkhorn@fkhealth.com tneyarapally@gnsbiotech.com
SOURCE Gene Network Sciences, Inc.
